The series A equips NMD to see whether the efficacy seen in models of myasthenia gravis and amyotrophic lateral sclerosis translates into the clinic.

Dracen will advance drugs that stifle a tumor's energy source and boost the immune response to cancer.

AbbVie is abandoning plans to seek out an FDA quick OK for its troubled oncology drug Rova-T in third-line relapsed/refractory small cell lung cancer.

The results come from a small, exploratory study Reata initiated after wrapping up a trial of the drug in its primary indication.

The drug discovery-stage company wants to tune the metabolism of immune cells to change their behavior.

Scientists at Dana-Farber Cancer Institute and Harvard have invented an immunotherapy “gel” that’s placed at the surgery site and is showing promising results…

If the pair finds potential treatments in the discovery deal, they will ink a new collaboration to advance them.

Beacon Capital's incubator will offer up to $50 million in seed funding, as well as office and lab space.

The biotech unveiled plans to sell 9 million shares hours before Kerrisdale Capital’s attack and abandoned them hours after it hit.

The funds will carry TCR2 into 2021, allowing it to bring its lead asset through clinical proof of concept.